ReviewZhongguo fei ai za zhi = Chinese journal of lung cancer2021
[Research Progress of Small Molecule Anti-angiogenic Drugs in Non-small Cell Lung Cancer].
Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.
- Pooled it
- Factors Contributing to the High Malignancy Level of Cholangiocarcinoma and Its Epidemiology: Literature Review and Data.Biology · 2025Review
- A single-center, retrospective study-spring-evaluating the efficacy and safety of recombinant human vascular endothelial inhibitor combined with anti-PD-1 in elderly patients aged 80 and above with NSCLC.Frontiers in immunology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is one of the cancers with the highest incidence in the world, and there is no standard treatment plan after second-line progression. Tumor angiogenesis has now been identified as an important therapeutic target for malignant tumors. Small molecule multi-target vascular kinase inhibitors can inhibit tumor angiogenesis by inhibiting angiogenesis-related signal pathways. At present, a lot of clinical trials of small molecule anti-angiogenic drugs for the treatment of non-small cell lung cancer (NSCLC) have been carried out, and some vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs) have been approved for the treatment of advanced NSCLC. Based on the development status of multiple small molecule anti-angiogenic drugs at home and abroad for the treatment of NSCLC, this article summarizes the efficacy and safety studies of multiple VEGFR-TKIs and fibroblast growth factor receptor (FGFR)-TKI single agents or combination treatments [including combined with chemotherapy, epidermal growth factor receptor (EGFR)-TKIs, immunotherapy, and radiotherapy, etc.] for NSCLC, and at the same time discussed the possible existence of VEGFR-TKIs drug resistance mechanisms and efficacy predictors, etc., and prospect the future development trend and potential problems of anti-vascular treatment of NSCLC, and provide new ideas for the follow-up precision and individualized treatment of lung cancer. .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.